Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955084 · ClinicalTrials.gov registry record · Phase 1
Maintenance Study on the Long Term Safety of XL999
A Phase 1 study of Advanced Malignancies, sponsored by Symphony Evolution.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT00955084 is a Phase 1 study of Advanced Malignancies that has completed, run by Symphony Evolution. The registered enrollment target is 2 participants, below the 89-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00955084, a Phase 1 study of Advanced Malignancies, has completed, sponsored by Symphony Evolution.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: * To evaluate tumor response after long term repeat administration of XL999 in two subjects rolled over from other XL999 studies. * To characterize the long term safety and tolerability of XL999 after repeat administration in two subjects rolled over from other XL999 studies. * To characterize the long term effects of XL999 on cardiac function after repeat administration in two subjects rolled over from other XL999 studies.
Conditions Studied
Interventions
- DRUG XL999
Study Locations (2)
New York
- Hematology Oncology Associates of Rockland Union State Bank Cancer Center - Nyack
Texas
- University of Texas Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955084
The ClinicalTrials.gov registry entry for NCT00955084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 10 other Advanced Malignancies trials with a reported enrollment target (98% lower). The listed sponsor is Symphony Evolution, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignancies appearing as the primary indexed condition, and to 1 intervention - of which XL999 is the first listed.
NCT00955084 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00955084 about?
NCT00955084 is a clinical study titled "Maintenance Study on the Long Term Safety of XL999". The primary objective of this study is to allow rollover of the two remaining subjects from the other XL999 studies to continue to receive XL999. The secondary objectives of this study are as follows: * To evaluate tumor response after long term repeat administration of XL999 in two subjects rolle...
What is the current status of trial NCT00955084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-08. Estimated completion is 2010-05.
What conditions does trial NCT00955084 study?
This clinical trial studies the following conditions: Advanced Malignancies.
What interventions are being tested in trial NCT00955084?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00955084?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00955084 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
COMPLETED · Phase 1
-
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
COMPLETED · Phase 1
-
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
COMPLETED · Phase 1
-
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.